TY - JOUR
T1 - Effects of the glucagon-like peptide-1receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease
T2 - A randomized, double-blind, placebo-controlled, crossover study
AU - Kumarathurai, Preman
AU - Anholm, Christian
AU - Fabricius-Bjerre, Andreas
AU - Nielsen, Olav W.
AU - Kristiansen, Ole
AU - Madsbad, Sten
AU - Haugaard, Steen B.
AU - Sajadieh, Ahmad
PY - 2017/5
Y1 - 2017/5
N2 - Objective: The glucagon-like peptide-1 receptor agonist liraglutide has been shown to reduce blood pressure (BP) in clinical trials using office BP measurements. However, the effects of liraglutide on 24-h BP and on the diurnal variation in BP have not been explored sufficiently. Methods: Forty-one patients with type 2 diabetes and stable coronary artery disease were randomized to receive liraglutide or placebo to a backbone therapy of metformin in this double-blind, placebo-controlled 12 along with 12 weeks crossover study. Ambulatory blood pressure monitoring (ABPM) was performed at the start and end of each intervention. Results: Twenty-four individuals completed all 24-h BP measurements. Liraglutide, when compared with placebo, did not induce any significant changes in mean 24-h SBP [difference R1.8mmHg (95% confidence interval, 95% CI:-4.33 to 7.93)] or DBP [+4.2mmHg (-0.74 to 9.17)]. Twenty-four-hour BP profiles revealed a trend for increase in evening SBP and DBP [+9.2mmHg (95% CI: 1.1-17.2) and R9.7mmHg (95% CI: 3.9-15.5), respectively]. Mean heart rate significantly increased after liraglutide [R7.6 bpm (95% CI: 2.56-12.62)]. Liraglutide did not affect the BP variability or the nocturnal BP dipping. Conclusions: We could not demonstrate any BP-lowering effect of liraglutide when using 24-h ABPM. Liraglutide exhibited diurnal variation in the effect on BP without affecting the BP variability or nocturnal BP dipping.
AB - Objective: The glucagon-like peptide-1 receptor agonist liraglutide has been shown to reduce blood pressure (BP) in clinical trials using office BP measurements. However, the effects of liraglutide on 24-h BP and on the diurnal variation in BP have not been explored sufficiently. Methods: Forty-one patients with type 2 diabetes and stable coronary artery disease were randomized to receive liraglutide or placebo to a backbone therapy of metformin in this double-blind, placebo-controlled 12 along with 12 weeks crossover study. Ambulatory blood pressure monitoring (ABPM) was performed at the start and end of each intervention. Results: Twenty-four individuals completed all 24-h BP measurements. Liraglutide, when compared with placebo, did not induce any significant changes in mean 24-h SBP [difference R1.8mmHg (95% confidence interval, 95% CI:-4.33 to 7.93)] or DBP [+4.2mmHg (-0.74 to 9.17)]. Twenty-four-hour BP profiles revealed a trend for increase in evening SBP and DBP [+9.2mmHg (95% CI: 1.1-17.2) and R9.7mmHg (95% CI: 3.9-15.5), respectively]. Mean heart rate significantly increased after liraglutide [R7.6 bpm (95% CI: 2.56-12.62)]. Liraglutide did not affect the BP variability or the nocturnal BP dipping. Conclusions: We could not demonstrate any BP-lowering effect of liraglutide when using 24-h ABPM. Liraglutide exhibited diurnal variation in the effect on BP without affecting the BP variability or nocturnal BP dipping.
KW - Ambulatory blood pressure monitoring
KW - Glucagon-like peptide-1
KW - Type 2 diabetes
U2 - 10.1097/HJH.0000000000001275
DO - 10.1097/HJH.0000000000001275
M3 - Journal article
C2 - 28129251
AN - SCOPUS:85010871771
SN - 0263-6352
VL - 35
SP - 1070
EP - 1078
JO - Journal of Hypertension
JF - Journal of Hypertension
IS - 5
ER -
